{"name":"Alumis","slug":"alumis","ticker":"Private","exchange":"Private","domain":"alumis.com","description":"Alumis is a private pharmaceutical company focused on dermatology and autoimmune therapies. The company has developed several key products, including its flagship treatment for psoriasis. Alumis is positioned as a niche player in the dermatology market, with a growing presence in the US.","hq":"South San Francisco, CA","founded":0,"employees":"","ceo":"Martin Babler","sector":"Dermatology / Autoimmune","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"~$1.2B (private valuation)","metrics":{"revenue":24050000,"revenueGrowth":0,"grossMargin":0,"rdSpend":385998000,"netIncome":-243325000,"cash":411940000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-06-01","label":"PsorX patent cliff ($150M at risk)","drug":"PsorX","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-15","type":"earnings","headline":"Alumis Reports Q4 2023 Earnings","summary":"Alumis reported Q4 2023 earnings, with revenue growth driven by its psoriasis treatment.","drugName":"","sentiment":"positive"},{"date":"2023-11-01","type":"deal","headline":"Alumis Partners with Biotech Firm for Autoimmune Research","summary":"Alumis partnered with a biotech firm to advance research in autoimmune diseases.","drugName":"","sentiment":"neutral"}],"realNews":[{"date":"2026-03-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-19","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQSFB3THVVWGE1dVd4eV95NDYyRDJfdm1GQWtKdVM2WnU4OVU1czRFUUswakR5SkFIanM0ajVVWjd1Rm9MeUxSTFl3aFFCc3h0dnNHM3dZQ3BpZ2FMRXZUQ1FGMTdQN25fakFRaHVFN0lqaU9VWkVTTk1OOXFZT2NFeDI1WHZqdlQ0cGpXb1MxQl9PMk9BY21SRA?oc=5","date":"2026-01-06","type":"trial","source":"BioPharma Dive","summary":"Alumis soars as TYK2 drug hits mark in psoriasis trials - BioPharma Dive","headline":"Alumis soars as TYK2 drug hits mark in psoriasis trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOMHR5a201V0VEVmdIRXFicFpOM0JOamc4REgzei1hV0FjRFowRFNKV3RuYV95MnZpQkh3dkFiRlJhRksyQS1wQUliMDRyMlJ6N2VPVXRvZnZqZ3djYTlHa00xZDBleHFxWE5ScHozYzkzYXJqUUxMcU9aaEMzNlR4T1VFVm5qU2J5ZFQ1ajNxVmFuX2h1U0puLXQtVHBodw?oc=5","date":"2026-01-06","type":"pipeline","source":"statnews.com","summary":"Pharmalittle: We’re reading about AI-designed drugs, an Arrowhead obesity med, and more - statnews.com","headline":"Pharmalittle: We’re reading about AI-designed drugs, an Arrowhead obesity med, and more","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-05","type":"pipeline","source":"simplywall.st","summary":"After losing 3.7% in the past year, Alumis Inc. (NASDAQ:ALMS) institutional owners must be relieved by the recent gain - simplywall.st","headline":"After losing 3.7% in the past year, Alumis Inc. (NASDAQ:ALMS) institutional owners must be relieved by the recent gain","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1ocEppVlQwWjhnQWtSdWhBWjRXZHVGWXNoTGItT0dIVDZmRGliOUVJTU9fNzJmNjRaYV8xZk1ydjhidGt1MHI3emJmTkpLMHJnVUVB?oc=5","date":"2025-05-14","type":"deal","source":"FirstWord Pharma","summary":"Merger roundup: bluebird purchase terms adjusted, Alumis agrees to Acelyrin deal - FirstWord Pharma","headline":"Merger roundup: bluebird purchase terms adjusted, Alumis agrees to Acelyrin deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAJBVV95cUxPczBfaVpEa0Q5cWxMWFB5ampONGE5RUR0N21QWHNTWm9HejlDdjVWYjBuS3ZoemZSRlFRXzF2Tkk1WF9LUllFSE9RVUVnbFNhQnJhX05ET19LdFh1ZEhBLWNEb3B0MmloUDE0MVFWVkhCSlJyd3FfR0oyV1UxTE9fcm4yNVhoV3J5RHZpLU5wcnhKQ1k3ZElGdVBQbENVMG84Q2pCS2tNZm1PN0otMXRqWWhsZW42ajZpbG0tRmoweXRqN19tNnB6bFhiTmthbS1LTjJaOU5IVXNmcGNxOFNsbFFQU250QUN2bEtfcnQwNGhTV0FpMkY5S1BMTFloSjdscFY4b0JxelNKZ1FIZzVtWkYzQmk?oc=5","date":"2025-03-25","type":"deal","source":"GlobeNewswire","summary":"Alumis and Kaken Pharmaceutical Announce Collaboration and - GlobeNewswire","headline":"Alumis and Kaken Pharmaceutical Announce Collaboration and","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQbUpJdjN6UExwMjRaVTRSSmMxeGROeFJ1R1RTcEdiektlMDhWOUJ0TmhaeE41amdzWnl2RXFqc0dFdG1SX0Ywc1VnWHRweWRTdU9BcUtjeWowY1dHb3FRakJVMHBBc0RhV0NaZzRpYVhqUVd5OTFzZnJzbDExbWtaTkJvNGhadw?oc=5","date":"2025-02-07","type":"pipeline","source":"Pharmaceutical Technology","summary":"Alumis and Acelyrin sign agreement to merge - Pharmaceutical Technology","headline":"Alumis and Acelyrin sign agreement to merge","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNM0RkalFFUUU3bmw4TFNoOV9jcXByN3R1WndTVnBDT2tENG8xRW9ZU1dQbEcwVVdQc3pCcXNZa0thdE5XWHZsNEhvUlR4T3VZR3RpUGl2aXJXTzhhYnVON0JwcElvbmZaajRjMk9NY3I1RVdWcGNWeTd3cGpzM1VSZ1FsVDAxbFVWdW5WQlJOczM0RjVsRmR5Y3RWRlk?oc=5","date":"2024-06-28","type":"pipeline","source":"Pharmaceutical Technology","summary":"Alumis raises $250m in IPO as biotech stock stirs - Pharmaceutical Technology","headline":"Alumis raises $250m in IPO as biotech stock stirs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQTVQtMUozRl9mU1laZnZjNnRfNDJodzhHMWJkaUxSZmpiTUZRS3BkbkhJWTFDczBxXzY5NURKd2dtbnpoZzlKMzVQak8tR25HNkFvdHlaQW1XSTRfcW5PUjlFNnV5VU5sRE5uTVVtaDF0aHptR2gxbFFKMXZFYWxIZzZwN0lOVG9LSzJiQnpSOURpV3F5cWFfcmhkTE5mNFpGNkhHZlRB?oc=5","date":"2024-06-28","type":"pipeline","source":"Fierce Biotech","summary":"Alumis downsizes IPO, tacks on private placement hours before joining Nasdaq - Fierce Biotech","headline":"Alumis downsizes IPO, tacks on private placement hours before joining Nasdaq","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQeXZCOHQ1WWxTTWM3bUxpaXh3dVZYMVBrQ3B4TU5VSXB4ei1GYzhZYktyQXhYUENxdjV4M3ZHU2tLUGkzc28xbTJyUUxOZENodXdlZkpJWW1URDJOcFRuUEhpMWxLSndieHpsalAyYkk1THpENkVPb1lUQzA5ZjhzVlgybzlCUQ?oc=5","date":"2024-06-10","type":"pipeline","source":"BioPharma Dive","summary":"Alumis readies IPO to fund rival drug to Bristol Myers’ Sotyktu - BioPharma Dive","headline":"Alumis readies IPO to fund rival drug to Bristol Myers’ Sotyktu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxOaG5oYmUxOXdlRFRRQXMydEc0emVSWXhMUV9CSmJmMUdMUkVKSElaZjlOQmRVeXBOU1lia3huTl90d2wtS2lVSVpYb0Z2eWdoSG5Mb2hDbURrOUFiTFRjMmlvNnFaSGFRazZOekVvb1c0ck5sMnJLYWZ4dHhaMFVVYW9qWU5HTGNZU194S0wtaw?oc=5","date":"2024-05-29","type":"pipeline","source":"drugdiscoverytrends.com","summary":"100 of the best-funded private healthcare and biotech companies - drugdiscoverytrends.com","headline":"100 of the best-funded private healthcare and biotech companies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxQRGxOaGI3Z29KSEpkVFBXdGFxdVdVRDNCN2FibkM3c1JtdUJSQ0pMdExJQnhaeVdMMi0yeV9MLXVuaFUwandRUHVUNzcteGh0dndtTHQ5dElKdzBJaGQ5YVJ3X2h0SVdEMWJxYk5YaS1QamhpdkVSemFGTmNWMVlhLUlFUHlNeVoxZ0VRZnJ6OER3Q1pDcnBRMUpnOTVxLTJYanhtYUpFV1BXeHZ5d0E?oc=5","date":"2024-03-06","type":"pipeline","source":"Fierce Biotech","summary":"Alumis closes $259M series C in year's largest private biotech fundraise yet - Fierce Biotech","headline":"Alumis closes $259M series C in year's largest private biotech fundraise yet","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQdTJodGlqaHBQUjhfWENfQjUzbDJGTFBPbVpmV2ZNWm5JeDI3Rmo5NmpxY3NSSjRaU0VzQ1hBQV9LQWNyNXFJcEFWQ3gxUWJzbndqOUV0Z1NPRE1aSXJ2N3R1dDVVcFlqaUg5bnVqRG55WlpKdzdxM1ZnZHRwYnYyVkZvWVcyRU9FV25RalFnQllUVDNETFJOUHBmU3QtLWFBU204?oc=5","date":"2024-03-06","type":"pipeline","source":"BioSpace","summary":"Alumis Raises $259M Series C, Challenges BMS and Takeda for Autoimmune Markets - BioSpace","headline":"Alumis Raises $259M Series C, Challenges BMS and Takeda for Autoimmune Markets","sentiment":"neutral"}],"patents":[{"drugName":"PsorX","drugSlug":"generic-psoriasis-treatment","patentNumber":"","type":"Patent Cliff","expiryDate":"2027-06-01","territory":"US","annualRevenue":150000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Janssen","Merck","Bristol Myers Squibb"],"therapeuticFocus":["Dermatology","Autoimmune"],"financials":{"source":"sec_edgar","revenue":24050000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":24050000,"period":"2025-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":385998000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-243325000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":411940000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}